BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 119 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $391,391 | -70.6% | 154,700 | -22.6% | 0.00% | – |
| Q2 2023 | $1,330,861 | -49.0% | 199,829 | +42.9% | 0.00% | – |
| Q1 2023 | $2,609,265 | -25.6% | 139,832 | -14.4% | 0.00% | – |
| Q4 2022 | $3,507,920 | +60.7% | 163,311 | -11.6% | 0.00% | – |
| Q3 2022 | $2,183,000 | -11.0% | 184,694 | -0.5% | 0.00% | – |
| Q2 2022 | $2,452,000 | -29.1% | 185,657 | +12.2% | 0.00% | – |
| Q1 2022 | $3,460,000 | -22.7% | 165,513 | -24.8% | 0.00% | – |
| Q4 2021 | $4,474,000 | -12.4% | 220,129 | +30.8% | 0.00% | – |
| Q3 2021 | $5,108,000 | -14.2% | 168,310 | -17.8% | 0.00% | -100.0% |
| Q2 2021 | $5,950,000 | -20.0% | 204,771 | +18.8% | 0.00% | 0.0% |
| Q1 2021 | $7,441,000 | -82.8% | 172,389 | -81.6% | 0.00% | -83.3% |
| Q4 2020 | $43,213,000 | +20.2% | 935,342 | +12.9% | 0.01% | +20.0% |
| Q3 2020 | $35,937,000 | +75.5% | 828,821 | +114.6% | 0.01% | +25.0% |
| Q2 2020 | $20,476,000 | +2391.0% | 386,262 | +949.6% | 0.01% | – |
| Q1 2020 | $822,000 | – | 36,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |